Recordati takeover bid raised to 53 euros by CVC and GBL

Respighi BidCo, the vehicle for CVC and GBL, said the revised cash offer values Recordati “fully and fairly” and reflects the company’s stand-alone prospects, while also acknowledging the recent deterioration in European healthcare and specialty pharma multiples. The tender period has been pushed to Oct. 23 from Oct. 15, giving investors more time to judge whether the new price is sufficient.

For investors, the key issue is whether the higher offer closes the gap between the consortium’s valuation and what Recordati shareholders see as fair value after a broader sector derating. Recordati has held up better than many healthcare names, but the bid increase suggests buyers are still willing to pay up for stable cash flows and defensive earnings visibility.

The move lands against a constructive opening tone in Europe, helped by Wall Street finishing near record highs, even as bond yields remain close to multi-year peaks and energy costs stay elevated. Germany’s August factory orders fell 10.6% month on month, underscoring that the region’s industrial recovery remains uneven despite the market’s upbeat start.

That split matters for asset allocators because it keeps the focus on stock-specific catalysts rather than a broad macro rerating. In Milan, shares of Recordati and other takeover-related names are drawing the most attention, while the wider market is also watching whether rising rates and weaker German demand start to bite harder into European earnings.

For CVC and GBL, the higher bid is a test of how far private equity can go in a market where financing costs are higher but listed valuations have already come down. The next catalyst is the response from Recordati shareholders before the extended Oct. 23 deadline.